EZH2 and ovarian carcinoma: While studies show in vitro cytotoxic effects of EZH2 inhibition against several ovarian cancer lines,58 the efficacy of EZH2 targeting is highly dependent on the mutational status of several other key epigenetic regulators, which can be cooperative or antagonistic to EZH2 function, rather than the mutational status of EZH2 itself (Figure 2).55, 59, 60, 61, 62, 63